Given the strong association between ATRX/H3.3 and PML-NBs, we sought to determine if pediatric glioma H3.3 mutations might exert oncogenic effects through disruption of PML-NBs, as is the case in APL. The gene discussed is ATRX; the disease is acute promyelocytic leukemia.